We are committed to help the pharmaceutical business with its research and development needs. Our services span every step of the research and development process, from lead optimisation and preclinical development to target discovery and validation. To successfully discover possible drug candidates, we use a multidisciplinary approach that includes computational toxicology, high-throughput screening, computational chemistry, in vitro pharmacology, toxicology, molecular biology, and disease pathway analysis. We provide significant data on how chemical compounds interact with biological targets, elucidating their pharmacological potential, using a variety of assays, including as receptor binding, enzyme inhibition, and cell-based functional assays. We provide several in vivo efficacy models to further confirm the pharmacodynamics of lead drugs, dosage response, and efficacy. Drug metabolism and pharmacokinetics (DMPK) studies, which assess absorption, distribution, metabolism, and excretion of compounds are another area of knowledge we expertise. The bioavailability, half-life, and clearance data from these investigations are crucial for predicting human profiles and optimising dosage schedules. Notably, our all-inclusive package is developed in accordance with the product specification to guarantee that it contains all required studies, such as IND and NDA enabling studies, impurity qualifying & bridging studies for regulatory submissions, and 505 (B2) methods. Along with developing suitable formulations for lead compounds, we work with our customers to improve their stability, bioavailability, and compliance. This ensures that prospective drug candidates are effectively delivered to the target location for the best possible therapeutic effects. Leading by subject matter experts, our interdisciplinary scientific team will assist our clients in submitting their projects successfully and on schedule.